AGM Statement

PHYSIOMICS ANNUAL GENERAL MEETING 2005

Oxford, UK 22 December 2005: At the Physiomics plc (AIM:PYC) Annual General
Meeting held today in the Magdalen Centre, Oxford, all resolutions were duly
passed.

                                   - ENDS -                                    

Notes to Editors

Physiomics plc

Physiomics plc (AIM:PYC) is a computational systems biology services company
applying simulations of cell behaviour to drug development to reduce the high
attrition rates of clinical trials. As 80-90 per cent of all clinical drug
candidates fail to reach the market, estimates show that an overall ten per
cent. improvement in success rates could reduce the cost of one drug's
development by as much as $242 million, from the current estimate of around
$800 million.

Physiomics is currently focused on optimising the design of cancer clinical
trials as a service to major pharmaceutical companies. In addition, it has
secured an option to in-license two innovative molecules in the cancer area
from Cronos Therapeutics. Physiomics has a major collaboration with Bayer
Technology Services GmbH to develop globally clinical response prediction
services using both companies' proprietary technologies and mathematical cell
models, including the SystemCell® technology developed by Physiomics. In June
2005, Physiomics became a distributor of Bayer's PK-Sim® product for
understanding the way pharmaceuticals are distributed round the body.
Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in
2004. For further information, please visit www.physiomics-plc.com

SystemCell is a registered trademark of Physiomics plc

For further information please contact:

Physiomics plc

Dr John Savin (CEO) Tel: + 44 1865 784 980

Northbank Communications Tel: + 44 207 886 8150

City/Financial Enquiries 

Emma Palmer

Scientific/Trade Press Enquiries

Fiona Brown/Rowan Minnion